期刊文献+

DOS方案辅助化疗对进展期胃癌的临床效果分析 被引量:2

Clinical effect of adjuvant chemotherapy with DOS regimen in advanced gastric cancer
下载PDF
导出
摘要 目的探讨进展期胃癌患者手术前给予多西他赛联合奥沙利铂和替吉奥(DOS)进行辅助化疗的临床疗效。方法选取实施手术治疗的进展期胃癌患者88例进行回顾性分析,根据治疗方法不同将患者分为化疗组与单纯手术组,每组各44例。其中化疗组患者手术前给予DOS方案进行辅助化疗,单纯手术组患者仅行手术治疗。对比两组患者的手术情况、手术不良反应和远期生存情况。结果化疗组44例患者中,有1例患者未能完成一个化疗周期,化疗的总有效率为95.35%;化疗组患者的术中出血量、阳性淋巴结数目均明显少于单纯手术组(P﹤0.001);化疗组患者的R_0切除率高于单纯手术组(P﹤0.05);化疗组患者的术后2年复发率低于单纯手术组,2年生存率高于单纯手术组,但差异均无统计学意义(P﹥0.05)。结论术前DOS方案辅助化疗治疗进展期胃癌有利于提高肿瘤的手术根治性效果,有利于患者的远期生存获益。 Objective To explore the clinical efficacy of preoperative adjuvant chemotherapy with the combination of docetaxel, oxaliplation and S-1(DOS) in patients with advanced gastric cancer. Method 88 cases of advanced gastric cancer patients who had undergone surgery were enrolled and retrospectively analyzed. The patients were divided into chemotherapy group and surgery alone group according to their treatment regimens, with 44 cases in each group. The patients in the chemotherapy group were given preoperative adjuvant chemotherapy with DOS regimen, and those in surgery alone group were treated with surgery alone. The surgery conditions, complications and long-term survival rate were compared between two groups. Result In the 44 patients of chemotherapy group, one patient failed to completed the first chemotherapy cycle, and the total effective rate of chemotherapy was 95.35%; the intraoperative blood loss and the number of positive lymph nodes in the chemotherapy group were significantly lower than those in the surgery alone group(P〈0.001). The R_0 resection rate in the chemotherapy group was higher than that in the surgery alone group(P〈0.05); the 2-year recurrence rate after surgery in chemotherapy group was lower than that in surgery alone group, while the 2-year survival rate in chemotherapy group was higher than that in surgery alone group, but there was no statistically significant difference observed(P〈0.05). Conclusion Preoperative DOS adjuvant chemotherapy is conducive to improving the efficacy of radical surgery for advanced gastric cancer, and has a beneficial impact on long-term survival.
出处 《癌症进展》 2017年第6期673-675,691,共4页 Oncology Progress
关键词 进展期胃癌 多西他赛 奥沙利铂 替吉奥 辅助化疗 advanced gastric cancer docetaxel oxaliplatin S-1 adjuvant chemotherapy
  • 相关文献

参考文献13

二级参考文献113

  • 1阮新建,张书霞,贾得前,宋飞翔.奥沙利铂联合替吉奥治疗晚期胃癌的临床观察[J].实用癌症杂志,2014,29(1):51-52. 被引量:7
  • 2Cunningham D,Allum WH,Stenning SP,菅鑫妍.手术期间化学疗法与单独手术治疗可切除的胃食管癌疗效比较[J].中国处方药,2006,5(8):59-60. 被引量:434
  • 3马佩炯,郑小青,张逸仲,熊益敏.胃镜、B超、CT在进展期胃癌的应用价值[J].临床和实验医学杂志,2007,6(8):14-15. 被引量:4
  • 4孙燕,周际昌.临床肿瘤内科手册[M].3版.北京:人民卫生出版社,1998:24-54.
  • 5张天泽 徐光炜.肿瘤学[M].天津:天津科学技术出版社,1998.1446.
  • 6Van Cutsem E. The treatment of advanced gastric cancer: new flndigs on the at,t f the taxanes . Ocglst, 2004,9 (2) :9-15.
  • 7Whiting G, Sano T, Saka M, et al. Follow-up of gastric cancer:a review[J]. Gastric Cancer, 2006,9(2) :74-81.
  • 8Bokn N. Chemotherapy for metastatic disease: review from JCOG triMs[J]. Int J Clin Oneol, 2008,13(3) :196-200.
  • 9Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer ( SPIR- ITS trial) : a phase llI trim [J]. Lancet Oncol, 2008,9(3) :215- 221.
  • 10Nakashima K, Hironak S, Boku N, et al. Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution [ J], Jpn J Clin Oncol, 2008, 38(12) :810-815.

共引文献943

同被引文献25

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部